Showing results (941-950 of 1,963) with videos related to

Sort By:
Pageof 197
RMD Open|July 3, 2026
Treat-to-target strategies are feasible in elderly-onset rheumatoid arthritis given its reassuring risk-benefit profileHamit Harun Dag, Marloes G B van Onna, Radboud J E M Dolhain, et al.
RMD Open|July 3, 2026
Beyond genotype: clustering analysis highlights clinical heterogeneity in paediatric familial Mediterranean feverIsild Mahé, Claire Billard, Federica Anselmi, et al.
RMD Open|July 3, 2026
Rare variants in genes related to inborn errors of immunity in patients with rheumatoid arthritis and secondary immunodeficiencyFaranaz Atschekzei, Natalia Dubrowinskaja, Manfred Anim, et al.
RMD Open|June 29, 2026
Dance as a double-edged sword: physiological adaptations, injury risks and therapeutic potentialAndrea Hinojosa-Azaola, Emma Renoult, Lise Lam-Briand, et al.
RMD Open|June 24, 2026
No benefit of adding glucocorticoids to maintenance treatment in reducing the risk of major relapses in ANCA-associated vasculitis: real life data from a longitudinal cohort studyKaterina Chavatza, Chrysoula G Gialouri, Konstantinos Drougkas, et al.
RMD Open|June 24, 2026
Effects of biologic and targeted synthetic disease modifying antirheumatic drugs (b/tsDMARDs) on patient-reported outcome domains in rheumatoid arthritis: a systematic review and network meta-analysesLuuk van Esveld, Marijke van den Dikkenberg, Nathalie Luurssen-Masurel, et al.
RMD Open|June 24, 2026
Long-term safety and efficacy of upadacitinib compared with adalimumab in patients with rheumatoid arthritis: 7-year data from the SELECT-COMPARE studyRoy Fleischmann, Jerzy Swierkot, Patrick Durez, et al.
RMD Open|May 28, 2026
Induction of Cure in Early Arthritis (I CEA): results of a randomised clinical trial to compare three treatment strategies in recent onset undifferentiated arthritisIsabell S Nevins, Joy Ardjuna van der Pol, Lotte Van Ouwerkerk, et al.
RMD Open|May 13, 2026
Bimekizumab treatment for sustained improvements in patient symptoms and health-related quality of life to 3 years in axial spondyloarthritis: results from the BE MOBILE studies and their open-label extensionVictoria Navarro-Compán, Uta Kiltz, Philip J Mease, et al.
RMD Open|May 13, 2026
Relapse risk of lupus-related serositis according to immunosuppressive therapy: a national real-world studyElodie Fels, Cassandra Goncalves, Sandrine Jousse-Joulin, et al.
Pageof 197